Bill To Curb Mail-Order Moves

18 August 1996

The US Prescription Drug Benefit Equity Act (HR 3991), introduced this month by Representative Lowey, would end incentives by private and public health plans to encourage the use of mail-order pharmacy. The bill is backed by both the National Association of Retail Druggists and the National Association of Chain Drug Stores.

Under the bill, no health plan could provide for mail-order prescription drug coverage unless it also provided non-mail-order prescription drug coverage under equitable terms. It would also ban deductible or cost-sharing charges for the use of a local pharmacy, unless these were also imposed on the use of mail-order services.

Rep Lowey became concerned after she heard from a constituent, a priest, that the health plan in which his order is enrolled would not permit him to use his local pharmacy, reports the Pink Sheet.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight